These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 12374247)

  • 21. Mycophenolic acid (cellcept and myofortic) induced injury of the upper GI tract.
    Nguyen T; Park JY; Scudiere JR; Montgomery E
    Am J Surg Pathol; 2009 Sep; 33(9):1355-63. PubMed ID: 19542873
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcomes of placing dental implants in patients taking oral bisphosphonates: a review of 115 cases.
    Grant BT; Amenedo C; Freeman K; Kraut RA
    J Oral Maxillofac Surg; 2008 Feb; 66(2):223-30. PubMed ID: 18201600
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety of bisphosphonates.
    Orozco C; Maalouf NM
    Rheum Dis Clin North Am; 2012 Nov; 38(4):681-705. PubMed ID: 23137577
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An evaluation of the use of oral bisphosphonates and risk of esophageal cancer.
    Haber SL; McNatty D
    Ann Pharmacother; 2012 Mar; 46(3):419-23. PubMed ID: 22333262
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adverse effects of bisphosphonates.
    Abrahamsen B
    Calcif Tissue Int; 2010 Jun; 86(6):421-35. PubMed ID: 20407762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Awareness and education of patients receiving bisphosphonates.
    Bauer JS; Beck N; Kiefer J; Stockmann P; Wichmann M; Eitner S
    J Craniomaxillofac Surg; 2012 Apr; 40(3):277-82. PubMed ID: 21612939
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gastrointestinal side effect profile due to the use of alendronate in the treatment of osteoporosis.
    Aki S; Eskiyurt N; Akarirmak U; Tüzün F; Eryavuz M; Alper S; Arpacioğlu O; Atalay F; Kavuncu V; Kokino S; Kuru O; Nas K; Ozerbil O; Savaş G; Sendur OF; Soy D; Akyüz G;
    Yonsei Med J; 2003 Dec; 44(6):961-7. PubMed ID: 14703602
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mucosal pathology of the upper gastrointestinal tract associated with intensive chemotherapy in children: vitamin A supplements do not prevent lesions.
    Kokkonen J; Möttönen M; Karttunen TJ; Lanning M
    Pediatr Hematol Oncol; 2002; 19(3):181-92. PubMed ID: 11936731
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel composite endpoint to evaluate the gastrointestinal (GI) effects of nonsteroidal antiinflammatory drugs through the entire GI tract.
    Chan FK; Cryer B; Goldstein JL; Lanas A; Peura DA; Scheiman JM; Simon LS; Singh G; Stillman MJ; Wilcox CM; Berger MF; Breazna A; Dodge W
    J Rheumatol; 2010 Jan; 37(1):167-74. PubMed ID: 19884267
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent developments in bisphosphonate therapy.
    Silverman SL; Maricic M
    Semin Arthritis Rheum; 2007 Aug; 37(1):1-12. PubMed ID: 17303219
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral bisphosphonates as a cause of bisphosphonate-related osteonecrosis of the jaws: clinical findings, assessment of risks, and preventive strategies.
    Assael LA
    J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):35-43. PubMed ID: 19371813
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of gastrointestinal events and osteoporosis treatment initiation in newly diagnosed osteoporotic Israeli women.
    Yu J; Goldshtein I; Shalev V; Chodick G; Ish-Shalom S; Sharon O; Modi A
    Int J Clin Pract; 2015 Sep; 69(9):1007-14. PubMed ID: 26278464
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
    Woodis CB
    Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gastrointestinal safety of an extended-release, nondeformable, oral dosage form (OROS: a retrospective study.
    Bass DM; Prevo M; Waxman DS
    Drug Saf; 2002; 25(14):1021-33. PubMed ID: 12408733
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral Bisphosphonates and Upper Gastrointestinal Cancer Risks in Asians with Osteoporosis: A Nested Case-Control Study Using National Retrospective Cohort Sample Data from Korea.
    Jung SY; Sohn HS; Park EJ; Suh HS; Park JW; Kwon JW
    PLoS One; 2016; 11(3):e0150531. PubMed ID: 26937968
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gastrointestinal adverse effects of bisphosphonates: etiology, incidence and prevention.
    Lanza FL
    Treat Endocrinol; 2002; 1(1):37-43. PubMed ID: 15765619
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Upper gastrointestinal safety of oral bisphosphonate in hospitalized patients.
    Nguyen PV; Bouin M; Ste-Marie LG
    Osteoporos Int; 2021 Jan; 32(1):193-197. PubMed ID: 32666144
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exposure to oral bisphosphonates and risk of esophageal cancer.
    Cardwell CR; Abnet CC; Cantwell MM; Murray LJ
    JAMA; 2010 Aug; 304(6):657-63. PubMed ID: 20699457
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The gastrointestinal tolerability and safety of oral bisphosphonates.
    Marshall JK
    Expert Opin Drug Saf; 2002 May; 1(1):71-8. PubMed ID: 12904162
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Renal safety in patients treated with bisphosphonates for osteoporosis: a review.
    Miller PD; Jamal SA; Evenepoel P; Eastell R; Boonen S
    J Bone Miner Res; 2013 Oct; 28(10):2049-59. PubMed ID: 23907861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.